CXCL1 and Patent ductus arteriosus: In brief, they found that H3K4me3 modification at the Cxcl1 promoter enhances the expression of CXCL1 in PDA tumor cell clones, leading to low infiltration of T cells and DCs, and the recruitment of MDSCs, which shapes the TIME and influences the outcome of immunotherapy (108).